Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (451-460 of 666) with videos related to

Pageof 67
Sort By:
Kidney International|September 1, 2023
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney diseaseKam Wa Chan, J David Smeijer, Meir Schechter, et al.
BMJ (Clinical Research Ed.)|November 30, 2021
Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort studyEdouard L Fu, Marie Evans, Juan-Jesus Carrero, et al.
Clinical Kidney Journal|December 4, 2023
The impact of gender on the risk of cardiovascular events in older adults with advanced chronic kidney diseaseMegan Astley, Fergus J Caskey, Marie Evans, et al.
American Journal of Nephrology|February 7, 2018
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes StudyMelanie P Chin, George L Bakris, Geoffrey A Block, et al.
Journal of Cardiac Failure|August 8, 2021
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME TrialGianluigi Savarese, Alicia Uijl, Lars H Lund, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 30, 2017
Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosagesJohannes Krämer, Malte Lenders, Sima Canaan-Kühl, et al.
Diabetes, Obesity & Metabolism|November 29, 2022
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registryStephan Kress, Peter Bramlage, Reinhard W Holl, et al.
Journal of the American Society of Nephrology : JASN|July 20, 2021
High Oxalate Concentrations Correlate with Increased Risk for Sudden Cardiac Death in Dialysis PatientsAnja Pfau, Theresa Ermer, Steven G Coca, et al.
European Journal of Heart Failure|June 6, 2023
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trialMichael Böhm, Javed Butler, Marcin Krawczyk, et al.
Clinical Kidney Journal|December 13, 2024
Prescribing patterns in older people with advanced chronic kidney disease towards the end of lifeMatthew Letts, Nicholas C Chesnaye, Maria Pippias, et al.
Pageof 67

Showing results (451-460 of 666) with videos related to

Sort By:
Pageof 67
Kidney International|September 1, 2023
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney diseaseKam Wa Chan, J David Smeijer, Meir Schechter, et al.
BMJ (Clinical Research Ed.)|November 30, 2021
Timing of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort studyEdouard L Fu, Marie Evans, Juan-Jesus Carrero, et al.
Clinical Kidney Journal|December 4, 2023
The impact of gender on the risk of cardiovascular events in older adults with advanced chronic kidney diseaseMegan Astley, Fergus J Caskey, Marie Evans, et al.
American Journal of Nephrology|February 7, 2018
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes StudyMelanie P Chin, George L Bakris, Geoffrey A Block, et al.
Journal of Cardiac Failure|August 8, 2021
Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME TrialGianluigi Savarese, Alicia Uijl, Lars H Lund, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 30, 2017
Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosagesJohannes Krämer, Malte Lenders, Sima Canaan-Kühl, et al.
Diabetes, Obesity & Metabolism|November 29, 2022
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registryStephan Kress, Peter Bramlage, Reinhard W Holl, et al.
Journal of the American Society of Nephrology : JASN|July 20, 2021
High Oxalate Concentrations Correlate with Increased Risk for Sudden Cardiac Death in Dialysis PatientsAnja Pfau, Theresa Ermer, Steven G Coca, et al.
European Journal of Heart Failure|June 6, 2023
Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trialMichael Böhm, Javed Butler, Marcin Krawczyk, et al.
Clinical Kidney Journal|December 13, 2024
Prescribing patterns in older people with advanced chronic kidney disease towards the end of lifeMatthew Letts, Nicholas C Chesnaye, Maria Pippias, et al.
Pageof 67